成人抗NXP2抗体阳性皮肌炎患者的严重胃肠道受累
该回顾性队列研究纳入2012至2022年某院56例成人抗NXP2抗体阳性皮肌炎患者,其中10例出现胃肠道受累,表现为腹痛和黑便,中位滞后10个月,8例发生胃肠道穿孔,4例短期死亡;肠道病理见血管炎/血管病伴MxA高表达、平滑肌坏死和浆膜钙化,RNA测序提示I型干扰素激活、上皮间质转化和黏着斑通路可能参与;维得利珠单抗显示有前景的治疗信号,需进一步研究。
要点
- 成人NXP2+DM患者中胃肠道受累可表现为腹痛和黑便,中位在诊断后10个月、肌炎大部分消退时出现。
- 10例胃肠道受累者中8例在数周内发生胃肠道穿孔,5例接受8次手术,4例短期死亡。
- 伴胃肠道受累者更多出现间质性肺病和皮下钙质沉着等肌肉外系统性表现。
核心结论
- 胃肠道受累是成人NXP2+DM患者的一种独特并发症。
- 及时识别和靶向治疗可能挽救生命。
研究设计与样本
- 回顾性收集2012至2022年某院成人NXP2+DM队列数据。
- 对穿孔患者的肠道样本进行RNA测序,并与健康对照数据集比较。
主要发现
- 共收集56例成人NXP2+DM患者,其中10例有胃肠道受累。
- 胃肠道受累的初始表现为腹痛和黑便,中位在NXP2+DM诊断后10个月、肌炎大部分消退时出现。
- 10例胃肠道受累患者中8例在数周内发生胃肠道穿孔,5例随后接受8次手术干预,4例观察到短期死亡。
- 伴胃肠道受累的NXP2+DM患者更多出现间质性肺病和皮下钙质沉着等肌肉外系统性表现。
- 胃肠道病理特征包括血管炎/血管病伴MxA高表达、肠道平滑肌坏死和浆膜钙质沉着。
关键数值与推荐
- 基因表达谱验证了I型干扰素激活,并揭示上皮间质转化和黏着斑通路可能也有贡献。
- 维得利珠单抗(抗α4β7整合素单克隆抗体)显示出有前景的治疗信号,应进一步研究。
临床怎么用
- 作者结论认为,及时识别和靶向治疗可能挽救成人NXP2+DM伴胃肠道受累患者的生命。
- 作者认为维得利珠单抗显示有前景的治疗信号,应进一步研究。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Gastrointestinal (GI) involvements were scarcely reported in adult anti-nuclear matrix protein 2 (NXP2) dermatomyositis (NXP2+DM). In this study, we investigated the clinical, pathological and molecular features as well as treatment options of this rare yet life-threatening disease. METHODS: We retrospectively collected the data of the cohort of NXP2+ DM from 2012 to 2022 in our hospital. RNA sequencing was performed in intestinal samples of perforated patients compared with healthy controls data set. RESULTS: A total of 56 patients with adult NXP2+DM were collected including 10 cases with GI involvements. Abdominal pain and melena were the initial manifestations for GI involvements with a median 10-month time lag after the diagnosis of NXP2+DM when myositis largely subsided. Within weeks, GI perforation occurred in 8 of 10 patients, while five patients underwent eight surgical interventions subsequently. The short-term mortality was observed in four patients. NXP2+DM with GI involvements presented with more extramuscular systemic manifestations such as interstitial lung disease and subcutaneous calcinosis. The GI pathological features encompassed vasculitis/vasculopathy with high MxA expression, intestinal smooth muscle necrosis and serosal calcinosis. Gene expression profile validated the type-I interferon activation and revealed that epithelial mesenchymal transition and focal adhesion pathway may also contribute. Finally, vedolizumab, an anti-α4β7-integrin monoclonal antibody, exhibited promising therapeutic signals which should be further investigated. CONCLUSIONS: GI involvement is a unique complication in patients with adult NXP2+DM. Timely recognition and targeted therapy may turn out to be lifesaving.
引用
- Fu Y, Gu L, Chen J, et al. Severe gastrointestinal involvements in patients with adult dermatomyositis with anti-NXP2 antibody. RMD Open. 2024. PMID: 38199847. doi:10.1136/rmdopen-2023-003901
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。